PBH Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q3

FY2026Q4

FY2027Q1

286.93M

-1.17%

1.181

-3.18%

301.14M

+1.56%

1.403

+6.25%

257.64M

+3.25%

1.000

+5.26%

Estimates Revision

The market is revising Upward the revenue expectations for Prestige Consumer Healthcare Inc. (PBH) for FY2026, with the revenue forecasts being adjusted by 0.21% over the past three months. During the same period, the stock price has changed by 2.20%.

Revenue Estimates for FY2026

Revise Upward

+0.21%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+0.64%

In Past 3 Month

Stock Price

Go Up

+2.20%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast PBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBH is 77.75 USD with a low forecast of 71.00 USD and a high forecast of 88.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

71.00

Averages

77.75

High

88.00

Current: 0.000

Low

71.00

Averages

77.75

High

88.00

Scotiabank

Sector Perform

Outperform

upgrade

$99 -> $120

2025-12-18

Reason

Scotiabank

Price Target

$99 -> $120

2025-12-18

upgrade

Sector Perform

Outperform

Reason

Scotiabank upgraded Premium Brands to Outperform from Sector Perform with a price target of C$120, up from C$99. The firm cites merger synergies, expectants for meaningful de-leverage over the next 6-12 months, and the company's exposure to stronger consumer spending growth in the U.S. in 2026 for the upgrade.

TD Securities

NULL -> Buy

maintain

$145 -> $160

2025-12-18

Reason

TD Securities

Price Target

$145 -> $160

2025-12-18

maintain

NULL -> Buy

Reason

TD Securities raised the firm's price target on Premium Brands to C$160 from C$145 and keeps a Buy rating on the shares.

Canaccord

Buy

maintain

$116 -> $123

2025-12-18

Reason

Canaccord

Price Target

$116 -> $123

2025-12-18

maintain

Buy

Reason

Canaccord raised the firm's price target on Premium Brands to C$123 from C$116 and keeps a Buy rating on the shares.

Stifel

Buy

maintain

$106 -> $111

2025-12-18

Reason

Stifel

Price Target

$106 -> $111

2025-12-18

maintain

Buy

Reason

Stifel raised the firm's price target on Premium Brands to C$111 from C$106 and keeps a Buy rating on the shares.

RBC Capital

NULL -> Outperform

maintain

$120 -> $132

2025-12-18

Reason

RBC Capital

Price Target

$120 -> $132

2025-12-18

maintain

NULL -> Outperform

Reason

RBC Capital raised the firm's price target on Premium Brands to C$132 from C$120 and keeps an Outperform rating on the shares.

Canaccord

Susan Anderson

Buy

downgrade

$100 -> $88

2025-11-07

Reason

Canaccord

Susan Anderson

Price Target

$100 -> $88

2025-11-07

downgrade

Buy

Reason

Canaccord analyst Susan Anderson lowered the firm's price target on Prestige Consumer to $88 from $100 and keeps a Buy rating on the shares. The firm said they posted solid results and management noted that sales and earnings exceeded expectations due to Clear Eyes supply timing and the timing of certain retailer orders, though this will come out of 3Q now.

Valuation Metrics

The current forward P/E ratio for Prestige Consumer Healthcare Inc (PBH.N) is 13.04, compared to its 5-year average forward P/E of 14.40. For a more detailed relative valuation and DCF analysis to assess Prestige Consumer Healthcare Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

14.40

Current PE

13.04

Overvalued PE

16.04

Undervalued PE

12.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

11.59

Current EV/EBITDA

10.38

Overvalued EV/EBITDA

12.48

Undervalued EV/EBITDA

10.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.78

Current PS

2.64

Overvalued PS

3.18

Undervalued PS

2.38

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 622.44% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PBH News & Events

Events Timeline

No data

News

5.0

01-09Barron's

2026 Stock Market and Economic Forecast from Barron’s Roundtable Experts

8.5

01-02NASDAQ.COM

Prestige Consumer Acquires Pillar5 Pharma to Expand Eye Care Product Line

8.5

2025-12-10Globenewswire

Premium Brands Acquires Stampede for $662.5 Million

People Also Watch

Frequently Asked Questions

What is Prestige Consumer Healthcare Inc (PBH) stock price today?

The current price of PBH is 64.17 USD — it has increased 0.33 % in the last trading day.

What is Prestige Consumer Healthcare Inc (PBH)'s business?

Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.

What is the price predicton of PBH Stock?

What is Prestige Consumer Healthcare Inc (PBH)'s revenue for the last quarter?

Prestige Consumer Healthcare Inc revenue for the last quarter amounts to 274.11M USD, decreased -3.41 % YoY.

What is Prestige Consumer Healthcare Inc (PBH)'s earnings per share (EPS) for the last quarter?

Prestige Consumer Healthcare Inc. EPS for the last quarter amounts to 0.86 USD, decreased -21.10 % YoY.

What changes have occurred in the market's expectations for Prestige Consumer Healthcare Inc (PBH)'s fundamentals?

How many employees does Prestige Consumer Healthcare Inc (PBH). have?

Prestige Consumer Healthcare Inc (PBH) has 600 emplpoyees as of January 10 2026.

What is Prestige Consumer Healthcare Inc (PBH) market cap?

Today PBH has the market capitalization of 3.09B USD.